GO:0031769 glucagon receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031769 (glucagon receptor binding) is a molecular function defined as binding to a glucagon receptor, with the synonym glucagon receptor ligand.
• The glucagon receptor (GCGR) is a class B GPCR whose activation depends on ligand engagement at the orthosteric and extra-helical sites, and on arrestin recruitment for signaling and desensitization.
• Ligand binding determinants have been mapped using glucagon analogues modified in the N-terminal region, linking receptor binding to adenylate cyclase activity.
• The glucagon receptor family is regulated by lipid environment and membrane composition, which can alter ligand binding and downstream signaling.
• Receptor-derived glucagon-binding peptide probes enable specific glucagon assay systems, providing tools for detecting and quantifying glucagon receptor binding.
• Glucagon receptor binding is a therapeutic target in metabolic disease, with antagonists and agonists being explored for glycemic control and weight loss.
Description
Glucagon receptor binding (GO:0031769) is a molecular function that describes the binding of a ligand to a glucagon receptor. This term captures the initial molecular recognition event that precedes receptor activation and downstream signaling, and it is central to understanding how glucagon and related peptides exert their biological effects. The glucagon receptor is a class B G protein-coupled receptor (GPCR) that plays a key role in glucose homeostasis and energy metabolism, making its ligand-binding properties a major focus of metabolic research. Researchers study glucagon receptor binding to dissect the structural basis of ligand recognition, to develop receptor antagonists or agonists, and to understand how binding events translate into physiological responses. The availability of receptor-derived binding probes and well-characterized glucagon analogues has enabled quantitative assays of binding affinity and specificity. Because the glucagon receptor family is sensitive to lipid environment and membrane composition, binding studies must also consider how membrane context influences receptor-ligand interactions. This article synthesizes the current understanding of glucagon receptor binding, its structural and mechanistic features, and the experimental approaches used to study it.
glucagon receptor binding At A Glance
| GO ID | GO:0031769 |
|---|---|
| GO term | glucagon receptor binding |
| Ontology | molecular_function |
| Synonym | glucagon receptor ligand |
| Definition | Binding to a glucagon receptor. |
| Major function | Ligand recognition at the glucagon receptor, enabling receptor activation or modulation. |
| Related receptor | Glucagon receptor (GCGR), a class B GPCR. |
| Related ligands | Glucagon and glucagon analogues; receptor-derived binding peptides. |
| Research relevance | Target for metabolic disease therapies and for structural studies of GPCR-ligand interactions. |
What Is GO:0031769?
According to the Gene Ontology, GO:0031769 (glucagon receptor binding) is defined as binding to a glucagon receptor. The term is classified under molecular_function and carries the synonym glucagon receptor ligand. In practice, this means the function describes the selective interaction between a ligand (such as glucagon or a synthetic analogue) and the glucagon receptor protein, without specifying downstream signaling outcomes.
Why Is glucagon receptor binding Important in Cell Biology?
Glucagon receptor binding is important because it is the first step in glucagon signaling, which regulates blood glucose, lipid metabolism, and energy balance. Understanding this binding event at the molecular level informs the design of antagonists and agonists for diabetes and obesity, and it provides a model for studying class B GPCR pharmacology. Moreover, the binding interaction is influenced by the lipid environment, adding a layer of regulation that is relevant to both physiology and drug development.
• Defines the initial molecular recognition event for glucagon and related ligands at the glucagon receptor.
• Underpins glucagon signaling that controls hepatic glucose production and lipid metabolism.
• Provides a structural template for class B GPCR ligand binding and allosteric modulation.
• Enables development of glucagon receptor antagonists for glycemic control.
• Supports development of glucagon receptor agonists for weight loss and metabolic benefit.
• Offers tools such as receptor-derived binding peptides for specific glucagon assays.
• Links ligand chemistry (e.g., N-terminal modifications) to receptor binding affinity and adenylate cyclase activity.
• Highlights the role of membrane lipids in modulating receptor-ligand interactions.
• Facilitates comparative studies with related receptors such as GLP-1 receptor.
• Guides CRISPR-based models to test the function of receptor-binding determinants in cells and animals.
Molecular Mechanism of glucagon receptor binding
Ligand recognition at the orthosteric site
In simple terms: The ligand first docks into the main binding pocket of the receptor.
Glucagon and its analogues bind to the glucagon receptor through interactions that involve the receptor's extracellular domain and transmembrane helices. Studies using N-terminal modified glucagon analogues have shown that changes in the ligand's N-terminal region can alter receptor binding affinity and adenylate cyclase activity, indicating that this region is critical for productive binding. The orthosteric site accommodates the ligand's key residues, and binding triggers conformational changes that lead to G protein activation.
Extra-helical binding site and allosteric modulation
In simple terms: Some molecules bind outside the main pocket and change how the receptor works.
Structural and pharmacological studies have identified an extra-helical binding site on the glucagon receptor that can be occupied by antagonists. This site is distinct from the orthosteric pocket and provides a mechanism for allosteric modulation of receptor activity. The existence of this site expands the opportunities for designing ligands that fine-tune glucagon receptor signaling.
Arrestin recruitment and tail engagement
In simple terms: After activation, the receptor recruits arrestin, which can shape signaling and desensitization.
Following ligand binding, the glucagon receptor can recruit arrestin proteins. A recent structure of arrestin engaged with the glucagon receptor tail revealed how arrestin interacts with the receptor's C-terminal region, providing insights into the molecular basis of arrestin-mediated signaling and desensitization. This interaction is a key step that links binding to downstream cellular responses.
Lipid regulation of receptor binding
In simple terms: The fat environment around the receptor can affect how well ligands bind.
The glucagon receptor family is sensitive to lipid composition, and membrane lipids can modulate receptor function and ligand binding. A review of lipid regulation of the glucagon receptor family highlights that cholesterol and other lipids can influence receptor conformation and signaling, thereby affecting binding events. This adds a layer of physiological regulation that is important for interpreting binding assays.
Receptor-derived binding probes and assay development
In simple terms: Scientists have made peptide probes from the receptor to detect glucagon specifically.
A specific glucagon assay system has been developed using a receptor-derived glucagon-binding peptide probe. This probe enables sensitive and specific detection of glucagon, demonstrating that receptor-derived sequences can be used to study binding interactions. Such tools are valuable for quantifying glucagon levels and for screening ligands that modulate receptor binding.
Key Genes Involved in GO:0031769 glucagon receptor binding
The following genes and proteins are central to glucagon receptor binding and its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GCGR | Encodes the glucagon receptor, the primary binding partner for glucagon. | Target for structural studies and drug development. |
| GCG | Encodes glucagon, the endogenous ligand that binds GCGR. | Ligand used in binding assays and analogue design. |
| GLP1R | Encodes the GLP-1 receptor, a related class B GPCR. | Comparative binding determinant studies. |
| ARRB1 | Encodes beta-arrestin-1, involved in receptor desensitization. | Studied for arrestin recruitment to GCGR. |
| ARRB2 | Encodes beta-arrestin-2, involved in receptor internalization. | Potential role in GCGR trafficking. |
| GNAS | Encodes Gs alpha subunit, couples to GCGR for cAMP production. | Downstream signaling of glucagon receptor binding. |
| ADCY | Encodes adenylate cyclase, produces cAMP upon Gs activation. | Measured as readout of receptor binding and activation. |
| PKA | Protein kinase A, activated by cAMP. | Downstream effector of glucagon signaling. |
| EPAC | Exchange protein activated by cAMP. | Alternative cAMP effector in glucagon signaling. |
| GRK2 | G protein-coupled receptor kinase 2, phosphorylates activated receptors. | Regulates desensitization of GCGR. |
| GRK5 | G protein-coupled receptor kinase 5, phosphorylates GPCRs. | Potential regulator of GCGR. |
| SLC2A2 | GLUT2 glucose transporter, downstream of glucagon action. | Metabolic readout in hepatocytes. |
| PCK1 | Phosphoenolpyruvate carboxykinase 1, gluconeogenic enzyme. | Glucagon-stimulated gene expression. |
| G6PC | Glucose-6-phosphatase, gluconeogenic enzyme. | Glucagon-regulated gene. |
| FOXO1 | Transcription factor downstream of glucagon signaling. | Mediates glucagon effects on gene expression. |
| CREB1 | cAMP response element-binding protein, transcription factor. | Mediates glucagon-induced transcription. |
| INSR | Insulin receptor, counter-regulatory to glucagon. | Context for metabolic studies. |
How Is glucagon receptor binding Regulated?
Glucagon receptor binding is regulated at multiple levels. The lipid environment of the membrane can modulate receptor conformation and ligand affinity, as reviewed for the glucagon receptor family. Receptor phosphorylation by GRKs and subsequent arrestin recruitment provide a mechanism for desensitization and internalization after ligand binding. Additionally, the presence of extra-helical binding sites allows for allosteric regulation by small molecules or antagonists. These regulatory layers ensure that glucagon signaling is tightly controlled in response to metabolic demands.
glucagon receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GCGR | Type 2 diabetes, obesity | Knockout mouse, point-mutation knock-in for binding site residues. |
| GCG | Hypoglycemia, metabolic syndrome | Overexpression of glucagon analogues in cell models. |
| ARRB1 | Metabolic regulation, desensitization | Knockout cell lines to study arrestin recruitment. |
| GNAS | Pseudohypoparathyroidism, metabolic disorders | Point mutations to disrupt Gs coupling. |
| GLP1R | Diabetes, obesity | Comparative binding studies with GCGR. |
Metabolic disorders: diabetes and obesity
Glucagon receptor binding is directly linked to glucose homeostasis. Antagonists of the glucagon receptor have been investigated for their ability to lower blood glucose in diabetes, and agonists are being explored for weight loss. A study in diet-induced obese mice showed that bile acid binding resins improve glucagon receptor agonist-mediated weight loss, highlighting the interplay between glucagon receptor binding and metabolic regulation. These findings underscore the therapeutic potential of modulating glucagon receptor binding in metabolic diseases.
Therapeutic targeting of the glucagon receptor
The identification of an extra-helical binding site on the glucagon receptor has provided a structural basis for designing antagonists that bind outside the orthosteric pocket. This has implications for developing drugs that can selectively block glucagon action without fully competing with the natural ligand, potentially reducing side effects. The clinical relevance of glucagon receptor binding is further supported by ongoing efforts to optimize agonists and antagonists for metabolic benefit.
Assay development and biomarker discovery
Specific assays for glucagon using receptor-derived binding peptides have been developed, which can aid in diagnosing and monitoring conditions related to glucagon dysregulation. Such tools are valuable for both research and clinical applications, enabling precise measurement of glucagon levels and screening for compounds that modulate receptor binding.
From glucagon receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GCGR binding site mutation affect ligand affinity? | Point-mutation knock-in of GCGR in HEK293 cells. |
| What is the role of arrestin in GCGR signaling? | ARRB1/ARRB2 knockout cells. |
| Can glucagon analogues with modified N-terminus alter receptor binding? | Overexpression of GCGR with analogue treatment. |
| How does lipid environment affect GCGR binding? | Membrane lipid modulation in cell culture. |
| Is GCGR required for glucagon-mediated glucose production? | Liver-specific GCGR knockout mice. |
| Can receptor-derived peptides detect glucagon specifically? | Tagged knock-in of binding peptide for assay development. |
How to Study the glucagon receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Receptor affinity and competition | Characterizing glucagon analogues. |
| cAMP assay | Gs-mediated signaling | Functional readout of receptor activation. |
| Cryo-EM | 3D structure of receptor-arrestin complex | Understanding arrestin engagement. |
| X-ray crystallography | Atomic structure of receptor-ligand complex | Identifying extra-helical binding sites. |
| Peptide probe assay | Specific glucagon detection | Quantifying glucagon in samples. |
| Lipid modulation | Effect of membrane lipids on binding | Studying lipid regulation. |
| Site-directed mutagenesis | Role of specific residues in binding | Mapping binding determinants. |
| BRET/FRET | Real-time receptor-ligand interaction | Live-cell binding kinetics. |
Radioligand binding assays
Radioligand binding assays using iodinated glucagon or analogues are classic methods to measure receptor binding affinity and competition. These assays have been used to characterize glucagon analogues modified in the N-terminal region, linking binding to adenylate cyclase activity. They provide quantitative data on dissociation constants and receptor density.
cAMP accumulation assays
cAMP accumulation assays measure downstream signaling after glucagon receptor binding. Because glucagon receptor activation leads to Gs-mediated adenylate cyclase stimulation, cAMP levels serve as a functional readout of binding and activation. These assays are often used in high-throughput screening for receptor ligands.
Structural biology: cryo-EM and X-ray crystallography
Structural techniques such as cryo-electron microscopy have been used to determine the structure of arrestin engaged with the glucagon receptor tail, revealing molecular details of the binding interface. X-ray crystallography has identified extra-helical binding sites for antagonists, providing templates for drug design. These methods offer atomic-level insights into glucagon receptor binding.
Peptide-based detection assays
Receptor-derived glucagon-binding peptide probes have been developed for specific glucagon assays. These probes can be used in ELISA-like formats or biosensors to detect glucagon with high specificity, enabling studies of glucagon secretion and binding. Such assays complement traditional radioimmunoassays.
How CRISPR Can Be Used to Study GO:0031769 glucagon receptor binding
Knockout
CRISPR knockout of GCGR or downstream signaling genes can abolish glucagon receptor binding and signaling, providing a clean background to study ligand specificity. For example, GCGR knockout cells or mice are used to confirm that observed effects are receptor-mediated. Knockout of ARRB1/ARRB2 can reveal the role of arrestin in receptor desensitization after binding.
Point Mutation
Point mutations introduced by CRISPR can alter specific residues in the glucagon receptor binding pocket or in the ligand. This approach helps map the contribution of individual amino acids to binding affinity and selectivity, as demonstrated by studies of glucagon analogues with N-terminal modifications. Point mutations in the extra-helical site can also test allosteric modulation.
Knock-in
Knock-in of tagged or reporter versions of GCGR allows visualization and tracking of receptor binding in live cells. For instance, a tagged receptor can be used in BRET/FRET assays to monitor ligand binding kinetics. Knock-in of receptor-derived binding peptides can create cell lines for specific glucagon detection.
Overexpression
Overexpression of GCGR in heterologous cells is commonly used to study ligand binding with high receptor density. This approach enhances signal-to-noise in binding assays and enables structural studies. Overexpression of glucagon or analogues can also be used to study autocrine/paracrine effects.
How EDITGENE Supports glucagon receptor binding Research
Researchers studying glucagon receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor activation, or downstream metabolic effects. This requires precise genetic models that can isolate the contribution of specific residues or signaling pathways.
Contact EDITGENE today to design your custom CRISPR model for glucagon receptor binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GCG Knockout HEK293 Cell Line | EDJ-KQ1765 | Human | 2641 | Details Get a Quote |
| GIP Knockout HEK293 Cell Line | EDJ-KQ1766 | Human | 2695 | Details Get a Quote |
| GIP Knockout A-549 Cell Line | EDJ-KQ21639 | Human | 2695 | Details Get a Quote |
| GCG Knockout HeLa Cell Line | EDJ-KQ53314 | Human | 2641 | Details Get a Quote |
| GIP Knockout HeLa Cell Line | EDJ-KQ53342 | Human | 2695 | Details Get a Quote |
| GCG Knockout A-549 Cell Line | EDJ-KQ61797 | Human | 2641 | Details Get a Quote |
| GCG Knockout HCT 116 Cell Line | EDJ-KQ70282 | Human | 2641 | Details Get a Quote |
| GIP Knockout HCT 116 Cell Line | EDJ-KQ70309 | Human | 2695 | Details Get a Quote |
Displaying Records 1 To 8 Of 8 Records
Frequently Asked Questions About glucagon receptor binding
What is glucagon receptor binding?
Glucagon receptor binding (GO:0031769) is a molecular function defined as binding to a glucagon receptor. It describes the selective interaction between a ligand such as glucagon and the glucagon receptor protein.
What genes are involved in glucagon receptor binding?
Key genes include GCGR (encoding the receptor), GCG (encoding glucagon), and downstream signaling genes such as GNAS and ARRB1/ARRB2.
What is the GO ID for glucagon receptor binding?
The Gene Ontology ID is GO:0031769, classified under molecular_function.
How is glucagon receptor binding studied?
Common methods include radioligand binding assays, cAMP accumulation assays, cryo-EM, X-ray crystallography, and peptide-based detection assays.
What is the role of arrestin in glucagon receptor binding?
Arrestin is recruited to the activated glucagon receptor and engages the receptor tail, contributing to signaling and desensitization after ligand binding.
Can glucagon receptor binding be targeted for diabetes treatment?
Yes, glucagon receptor antagonists and agonists are being explored for glycemic control and weight loss, with binding at orthosteric and extra-helical sites as key targets.
What is the extra-helical binding site of the glucagon receptor?
It is a binding site outside the orthosteric pocket that can be occupied by antagonists, providing an allosteric mechanism to modulate receptor activity.
How do lipids affect glucagon receptor binding?
Membrane lipids can modulate receptor conformation and ligand affinity, as reviewed for the glucagon receptor family.
What are receptor-derived glucagon-binding peptides?
These are peptides derived from the glucagon receptor that can specifically bind glucagon and are used in assay systems for glucagon detection.
What CRISPR models are available for glucagon receptor binding research?
EDITGENE offers knockout, point mutation, knock-in, and overexpression models for GCGR and related genes, as well as CRISPR library screening and bioinformatics services.
Conclusion
Glucagon receptor binding (GO:0031769) is a fundamental molecular function that initiates glucagon signaling and is central to metabolic regulation. Structural and pharmacological studies have revealed distinct binding sites and regulatory mechanisms, including arrestin recruitment and lipid modulation. These insights have therapeutic implications for diabetes and obesity, with both antagonists and agonists advancing. Continued research using CRISPR models and advanced assays will further clarify the molecular details of glucagon receptor binding and its role in health and disease.
References
- 1. Chen K et al.. 2023. Tail engagement of arrestin at the glucagon receptor.. Nature 620(7975):904-910 PMID: 37558880
- 2. Jazayeri A et al.. 2016. Extra-helical binding site of a glucagon receptor antagonist.. Nature 533(7602):274-7 PMID: 27111510
- 3. Oqua AI et al.. 2024. Lipid regulation of the glucagon receptor family.. J Endocrinol 261(3) PMID: 38614123
- 4. Xiao Q et al.. 2000. Characterization of glucagon-like peptide-1 receptor-binding determinants.. J Mol Endocrinol 25(3):321-35 PMID: 11116211
- 5. McKee RL et al.. 1986. Receptor binding and adenylate cyclase activities of glucagon analogues modified in the N-terminal region.. Biochemistry 25(7):1650-6 PMID: 3011069
- 6. Kim T et al.. 2026. Bile Acid Binding Resins Improve Glucagon Receptor Agonist-Mediated Weight Loss in Diet-Induced Obese Mice.. Obesity (Silver Spring) 34(2):428-438 PMID: 41236053
- 7. Shigeto H et al.. 2026. Specific Glucagon Assay System Using a Receptor-Derived Glucagon-Binding Peptide Probe.. Int J Mol Sci 27(1) PMID: 41516388
- 8. Crunkhorn S. 2016. GPCRs: Glucagon receptor antagonist binding site identified.. Nat Rev Drug Discov 15(6):384 PMID: 27245394
